On August 8, 2024, MediciNova, Inc. (MNOV) filed form 10-Q with financial results for the second quarter of 2024. The company is conducting a Phase 3 clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS), which includes 12 months of double-blind treatment plus a six-month open label extension period. The primary endpoint is change from baseline in ALSFRS-R at Month 12 and survival time. We anticipate a data readout in 2025. The company is also conducting a Phase 2 trial of MN-001 (tipelukast) in patients with MASLD, Type 2 Diabetes, and hypertriglyceridemia and consists of 24 weeks of treatment. The co-primary endpoints are change from baseline in liver fat content and change from baseline in fasting serum triglycerides at Week 24.
